Head-to-head · WeighScore
Cost Plus Drugs vs Ivim Health
The verdict
Ivim Health takes it — 59.6/100 to 58.5/100, but only just.
Ivim Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ivim Health is a telehealth weight-loss programme selling compounded semaglutide starting at $149/mo and compounded tirzepatide starting at $224/mo, each quoted with medication and programme charges included. Cost Plus Drugs is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Cost Plus Drugs | Ivim Health |
|---|---|---|
| WeighScore | 58.5/100 | 59.6/100 |
| Grade | C | C |
| Scorecard rank | #370 | #338 |
| Semaglutide | $279/mo (brand Ozempic) | $149/mo (starting dose, medication and programme fee, compounded) |
| Tirzepatide | Not disclosed | $224/mo (starting dose, medication and programme fee, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #370 · C
Strengths
- Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
- Around $279/mo for branded Ozempic — well below typical retail list prices
- Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
- Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
- Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing
Where it loses points
- Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
- Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
- Wegovy availability has been spotty — check current stock before assuming it ships
- No compounded semaglutide or tirzepatide — brand only
- No clinical follow-up — side-effect monitoring falls to your prescribing clinician
Graded #338 · C
Strengths
- Both molecules are priced on one page, each quoted as medication and programme charge included rather than as a bare drug price
- A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
- The first month of the membership is free
Where it loses points
- A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
- The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
- Both figures are 'starting at' rates, so the cost of a titrated dose is not published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.